抄録
Rationale: Regorafenib is effective for metastatic colorectal cancer but its toxicity such as hemorrhage should be considered. The safety of regorafenib for the patient with the liver disease is not known. Patient concerns: Seventy-one-year old man of colon cancer had myodesopsia and blood stool after 14 days from the initiation of regorafenib administration with 50% dose reduction due to liver dysfunction. Diagnoses: Fundus examination revealed hemorrhage of the retinal vein. Interventions: Regorafenib treatment was discontinued and observational therapy was pursued. Outcomes: Retinal and gastrointestinal hemorrhage resolved in 1 week. Lessons: Retinal hemorrhage should be considered as the differential diagnosis of myodesopsia in the patient treated by regorafenib. Safety and pharmacokinetic of continuous regorafenib administration for patients with liver dysfunction remains to be clarified.
| 元の言語 | 英語 |
|---|---|
| 記事番号 | e8285 |
| ジャーナル | Medicine (United States) |
| 巻 | 96 |
| 発行部数 | 42 |
| DOI | |
| 出版物ステータス | 出版済み - 10 1 2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
これを引用
Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction. / Tsuchihashi, Kenji; Shimokawa, Hozumi; Takayoshi, Kotoe; Nio, Kenta; Aikawa, Tomomi; Matsushita, Yuzo; Wada, Iori; Arita, Shuji; ariyama, hiroshi; Kusaba, Hitoshi; Sonoda, Kohei; Akashi, Koichi; Baba, Eishi.
：: Medicine (United States), 巻 96, 番号 42, e8285, 01.10.2017.研究成果: ジャーナルへの寄稿 › 記事
}
TY - JOUR
T1 - Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction
AU - Tsuchihashi, Kenji
AU - Shimokawa, Hozumi
AU - Takayoshi, Kotoe
AU - Nio, Kenta
AU - Aikawa, Tomomi
AU - Matsushita, Yuzo
AU - Wada, Iori
AU - Arita, Shuji
AU - ariyama, hiroshi
AU - Kusaba, Hitoshi
AU - Sonoda, Kohei
AU - Akashi, Koichi
AU - Baba, Eishi
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Rationale: Regorafenib is effective for metastatic colorectal cancer but its toxicity such as hemorrhage should be considered. The safety of regorafenib for the patient with the liver disease is not known. Patient concerns: Seventy-one-year old man of colon cancer had myodesopsia and blood stool after 14 days from the initiation of regorafenib administration with 50% dose reduction due to liver dysfunction. Diagnoses: Fundus examination revealed hemorrhage of the retinal vein. Interventions: Regorafenib treatment was discontinued and observational therapy was pursued. Outcomes: Retinal and gastrointestinal hemorrhage resolved in 1 week. Lessons: Retinal hemorrhage should be considered as the differential diagnosis of myodesopsia in the patient treated by regorafenib. Safety and pharmacokinetic of continuous regorafenib administration for patients with liver dysfunction remains to be clarified.
AB - Rationale: Regorafenib is effective for metastatic colorectal cancer but its toxicity such as hemorrhage should be considered. The safety of regorafenib for the patient with the liver disease is not known. Patient concerns: Seventy-one-year old man of colon cancer had myodesopsia and blood stool after 14 days from the initiation of regorafenib administration with 50% dose reduction due to liver dysfunction. Diagnoses: Fundus examination revealed hemorrhage of the retinal vein. Interventions: Regorafenib treatment was discontinued and observational therapy was pursued. Outcomes: Retinal and gastrointestinal hemorrhage resolved in 1 week. Lessons: Retinal hemorrhage should be considered as the differential diagnosis of myodesopsia in the patient treated by regorafenib. Safety and pharmacokinetic of continuous regorafenib administration for patients with liver dysfunction remains to be clarified.
UR - http://www.scopus.com/inward/record.url?scp=85032647234&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032647234&partnerID=8YFLogxK
U2 - 10.1097/MD.0000000000008285
DO - 10.1097/MD.0000000000008285
M3 - Article
C2 - 29049226
AN - SCOPUS:85032647234
VL - 96
JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries
JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries
SN - 0025-7974
IS - 42
M1 - e8285
ER -